

ORIGINAL RESEARCH

Open Access

# Agonist signalling properties of radiotracers used for imaging of dopamine D<sub>2/3</sub> receptors

Jan-Peter van Wieringen<sup>1\*</sup>, Martin C Michel<sup>2</sup>, Henk M Janssen<sup>3</sup>, Anton G Janssen<sup>4</sup>, Philip H Elsinga<sup>5</sup> and Jan Booij<sup>1</sup>

## Abstract

**Background:** Dopamine D<sub>2/3</sub> receptor (D<sub>2/3</sub>R) agonist radiopharmaceuticals are considered superior to antagonists to detect dopamine release, e.g. induced by amphetamines. Agonists bind preferentially to the high-affinity state of the dopamine D<sub>2</sub>R, which has been proposed as the reason why agonists are more sensitive to detect dopamine release than antagonist radiopharmaceuticals, but this theory has been challenged. Interestingly, not all agonists similarly activate the classic cyclic adenosine mono phosphate (cAMP) and the β-arrestin-2 pathway, some stimulate preferentially one of these pathways; a phenomenon called biased agonism. Because these pathways can be affected separately by pathologies or drugs (including dopamine releasers), it is important to know how agonist radiotracers act on these pathways. Therefore, we characterized the intracellular signalling of the well-known D<sub>2/3</sub>R agonist radiopharmaceuticals NPA and PHNO and of several novel D<sub>2/3</sub>R agonists.

**Methods:** cAMP accumulation and β-arrestin-2 recruitment were measured on cells expressing human D<sub>2</sub>R.

**Results:** All tested agonists showed (almost) full agonism in both pathways.

**Conclusions:** The tested D<sub>2/3</sub>R agonist radiopharmaceuticals did not exhibit biased agonism *in vitro*. Consequently, it is likely that drugs (including psychostimulants like amphetamines) and/or pathologies that influence the cAMP and/or the β-arrestin-2 pathway may influence the binding of these radiopharmaceuticals.

**Keywords:** Dopamine D<sub>2/3</sub> receptor; PET/SPECT; Intracellular signalling

## Background

The dopamine (DA) system plays a central role in several neuropsychiatric disorders including Parkinson's disease and schizophrenia. DA D<sub>2</sub> receptor (D<sub>2</sub>R) antagonists are used to reduce psychotic symptoms, whereas D<sub>2</sub>R agonists are commonly used in the treatment of Parkinson's disease. Consequently, radiopharmaceuticals targeting D<sub>2</sub>R are of value to obtain insight in the pathophysiology of these brain disorders.

The D<sub>2</sub>R is a subfamily within the superfamily of G-protein-coupled receptors (GPCRs) and contains several subtypes including some in the D<sub>2</sub>-like subfamily, the D<sub>2</sub> (splice variants D<sub>2short</sub> (D<sub>2S</sub>) and D<sub>2long</sub> (D<sub>2L</sub>) [1]), D<sub>3</sub> and D<sub>4</sub> receptors [2]. They primarily couple to the G<sub>i/o</sub> type of G-proteins to inhibit the enzyme adenylyl cyclase in producing cyclic adenosine mono phosphate (cAMP) [2]. Like other GPCRs, they exhibit interconvertible

high- and low-affinity states for agonists *in vitro* [3]. In the high-affinity state, the receptor is coupled to the G-protein and this is considered to be the active state of the receptor. In the low-affinity state, the receptor is uncoupled and consequently inactive.

Dopamine D<sub>2/3</sub> receptor (D<sub>2/3</sub>R) agonist radiopharmaceuticals for positron emission tomography (PET) have been developed successfully (e.g. <sup>11</sup>C-NPA (N-propyl-nor-apomorphine) and <sup>11</sup>C-PHNO ((+)-4-propyl-9-hydroxy-naphthoxazine)), and such agonists are more sensitive in detecting DA release in humans compared to antagonists like <sup>11</sup>C-raclopride [4-7]. It has been proposed that the reason for this increased sensitivity may be that D<sub>2/3</sub>R agonist radiopharmaceuticals bind preferentially to the high-affinity state of the dopamine D<sub>2</sub>R, whereas antagonists do not differentiate between the high- and low-affinity states [8-10]. However, this proposal depends upon the existence of two affinity states *in vivo* and the results of recent studies challenged this theory [11-13].

\* Correspondence: j.vanwieringen@amc.uva.nl


<sup>1</sup>Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands  
Full list of author information is available at the end of the article

Originally, DA receptors (and other GPCRs) were thought to signal intracellularly only through their G-proteins. However, it was shown recently that besides this (canonical) pathway, DA receptors can also exert effects through proteins of which it was initially thought that they regulate receptor desensitization (non-canonical pathway, Figure 1). This cAMP-independent mechanism involves the adaptor protein  $\beta$ -arrestin-2. Compounds can have distinct patterns of responses on these pathways; this phenomenon is called 'biased agonism' or 'ligand-directed signalling' [14,15].

Activation of the  $\beta$ -arrestin-2 pathway may play a role in the increased sensitivity to detect dopamine release *in vivo*. Activation of this pathway eventually leads to the regulation of glycogen synthase kinase 3 (GSK3), a protein that is involved in many DA-dependent behaviours [16]. Many drugs (antipsychotics, antidepressants, lithium) affect this cascade, and recently compounds, based on the aripiprazole scaffold, were discovered that are functionally selective for the  $\beta$ -arrestin-2 pathway [17,18]. Consequently, it is important to characterize pharmacologically the intracellular pathways that DA

$D_{2/3}R$  agonist radiopharmaceuticals act on. This information is not only relevant when the radiopharmaceuticals are used to evaluate actions of novel drugs which may show biased agonism but also because  $\beta$ -arrestin-2 itself may be involved in the desensitization of DA receptors and as such in the detection of DA. Literature about biased signalling of currently available agonist PET radiotracers  $^{11}C$ -NPA and  $^{11}C$ -PHNO at cloned DA receptors does not exist, and therefore, we tested unlabelled ('cold') NPA and PHNO for agonism in both the cAMP and  $\beta$ -arrestin-2 assays.

Additionally, and in a broader perspective, we are developing new DA  $D_{2/3}R$  agonist radiotracers for PET and single-photon emission computed tomography (SPECT) imaging, where the investigated compounds are based on the 2-aminomethylchromane (AMC) scaffold. We have tested agonism for our AMC compounds by means of a cAMP assay and have found that most of these compounds showed full agonism for this canonical pathway [19]. As for NPA and PHNO, also for these new AMC tracers, we were interested to evaluate if they would show biased agonism. Finally, the  $D_{2/3}R$  antagonist SPECT



tracer  $^{123}\text{I}$ -iodobenzamide ( $^{123}\text{I}$ -IBZM) is used in many studies including studies on Parkinsonism [20] and on amphetamine-induced DA release [21]. Based on early studies in rats showing that IBZM was a potent inhibitor of an apomorphine-induced syndrome (apomorphine is a  $\text{D}_2\text{R}$  agonist) of hyperactivity and stereotypy, it was concluded that IBZM was a DA antagonist [22]. As no other research examining the functional agonism or antagonism of IBZM has been reported, we also tested IBZM for biased agonism. Of note, studies with other receptors show that antagonists for one signalling pathway of a receptor may be agonists for another pathway.

Accordingly, in this study, we have tested if clinically used as well as recently developed  $\text{D}_{2/3}\text{R}$  radiopharmaceuticals show biased agonism.

## Methods

The agonists *R*(-)-propylnorapomorphine HCl, pergolide mesylate and DA HCl were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). (+)PHNO HCl was obtained from Axon Medchem (Groningen, The Netherlands). The cold-labelled (i.e. iodine-127-labelled) antagonist iodo-6-methoxybenzamide (IBZM) was a kind gift of GE Healthcare (Eindhoven, The Netherlands). We have previously presented the synthesis and evaluation of a new group of cold-labelled  $\text{D}_{2/3}\text{R}$  agonist tracers based on an AMC scaffold, including (*R*)N-[7-hydroxychroman-2-yl]-methyl 4-iodobenzyl amine (codenamed 11a), (*R*)-2-[(4-(4-fluorobutoxy)benzylamino)methyl] chroman-7-ol (codenamed 12a) and (*R*)-1-(4-(2-fluoroethoxy)phenyl)-4-(4-(7-hydroxychroman-2-yl)-3-azabutyl)-piperazine (codenamed 12d) [19] (see Figure 2).

### cAMP accumulation assay and receptor binding assay

As described in detail earlier [19], cAMP accumulation was measured in HEK 293 cells stably expressing the human DA  $\text{D}_2\text{L}$  receptor with an assay from PerkinElmer

(Waltham USA). Receptor binding experiments were done on the membranes obtained from the above mentioned cells using  $^3\text{H}$ -spiperone as radioligand.

### $\beta$ -arrestin-2 recruitment assay

The PathHunter™ eXpress human DA receptor  $\text{D}_2\text{L}$  CHO-K1  $\beta$ -arrestin-2 GPCR assay from DiscoverX (Fremont, CA, USA) was used according to the manufacturer's protocol. Cells were seeded at a density of 8,000 cells/well in a 96-well plate in 100  $\mu\text{l}$  PathHunter™ CP reagent and incubated 48 h in a humidified atmosphere at 5%  $\text{CO}_2$  at 37°C. After 48 h, the compounds dissolved in Hank's balanced salt solution supplemented with 5 mM HEPES and 1.1% DMSO were added to the wells in duplo. Then a detection mixture was made and added to the wells. The cells were incubated for 60 min at room temperature, and subsequently chemiluminescence was measured on a Wallac Victor (PerkinElmer, Zaventem, Belgium).


## Results

### cAMP

In our previous studies the novel AMC compounds 11a, 12a and 12d bound with a high-affinity to the DA  $\text{D}_2$ -high receptor and were full agonists compared to DA itself; DA, 11a and 12a were similarly potent, and 12d was a little more potent [19]. NPA and PHNO were also full agonists, displaying  $E_{\text{max}}$  values even higher than those of DA that was set at 100% efficacy as a reference. Furthermore, NPA and PHNO were, respectively, 1 log and 2 log units more potent than DA. The SPECT tracer IBZM was an inverse agonist. All data are compiled in Table 1.

### $\beta$ -arrestin-2

NPA, PHNO, 11a, 12a and 12d demonstrated full agonism for this pathway (using DA as the 100% reference),



**Figure 2 The tested compounds.** The cold analogues of the clinically applied tracers NPA, PHNO and IBZM and from the developed series of AMC compounds 11a, 12a and 12d (published in [19]).

**Table 1 Radioligand binding and functional activities of different compounds\***

Compound	pK <sub>i</sub> D <sub>2</sub> -high	cAMP		β-arrestin-2	
		Potency	Efficacy	Potency	Efficacy
		pEC <sub>50</sub>	%	pEC <sub>50</sub>	%
Dopamine	6.97 <sup>†</sup>	9.22 <sup>†</sup>	100 <sup>†</sup>	6.97	100
NPA	10.13 <sup>†</sup>	10.31	118	9.67	103
PHNO	9.47 <sup>†</sup>	11.03	114	9.39	99
11a	8.69 <sup>†</sup>	9.16 <sup>†</sup>	86 <sup>†</sup>	8.26	81
12a	8.26 <sup>†</sup>	9.42 <sup>†</sup>	96 <sup>†</sup>	8.36	88
12d	8.30 <sup>†</sup>	9.82 <sup>†</sup>	94 <sup>†</sup>	8.61	88
IBZM	6.99 <sup>‡</sup>	9.08	Inverse agonist	-	Neutral antagonist

\*pK<sub>i</sub>, pEC<sub>50</sub> and E<sub>max</sub> values are the average of at least two duplicate experiments with standard deviations (SD) values that were less than a third of the mean.

<sup>†</sup>Parts published earlier in van Wieringen et al, 2014 [19].

<sup>‡</sup>For IBZM no high-affinity state was detected; pK<sub>i</sub> value represents affinity for the total number of D<sub>2</sub> receptors.

whereas IBZM was a neutral antagonist (Figure 3). In the β-arrestin-2 pathway, all tested compounds had higher potencies than DA (pEC<sub>50</sub> of 6.97) with NPA being the most potent (pEC<sub>50</sub> of 9.67). See Figure 3 and Table 1 for all data.

The potencies of all tested compounds, as measured in the two functional tests, correlated ( $r = 0.80$ ; Spearman's rank correlation).


## Discussion

We found that all agonist compounds tested that were active in the cAMP assays were also active in β-arrestin-2 recruitment with an efficacy similar to that of DA.

Moreover, the potencies of all agonists in the two functional assays were well correlated with a slope close to unity ( $1.046 \pm 0.3965$ ). However, their potency was consistently higher in the cAMP than in the β-arrestin-2 assay, especially for DA and PHNO. This may be explained by the presence of a receptor reserve in the cells used in the cAMP experiments causing signal amplification while the arrestin recruitment assay measures a more 1:1 interaction of the receptor to arrestin. All in all, the present data do not support biased agonism for these compounds.

Skinbjerg and colleagues recently demonstrated that the striatal binding potential (BP<sub>ND</sub>) of the agonist <sup>11</sup>C-MNPA and the antagonist (or inverse agonist; for discussion see below) <sup>18</sup>F-fallypride was not different in wild-type mice and β-arrestin-2 knockout mice [23]. The results of this study suggest that a modified arrestin pathway does not affect radiotracer binding during 'baseline' conditions, independent of agonist signalling properties of the radiotracer. A modification in the arrestin pathway is more likely to be demonstrated using a pharmacological challenge, as shown in the amphetamine studies by Skinbjerg and co-workers [23]. The current work, therefore, appears most relevant to drug interaction studies, and consequently may shed new light on the reason why agonist D<sub>2/3</sub>R radiopharmaceuticals are more sensitive to detect DA release than antagonists [4-7]. More specifically, it has been demonstrated that arrestin desensitizes the D<sub>2</sub>R and prepares it for internalization by hindering the coupling of the G-protein to the receptor. Consequently, the desensitized receptor is in the low-affinity state [24]. So, after agonist binding, the receptor is switched to the low-affinity state and kept in that state by arrestin; thus, theoretically the density of D<sub>2</sub> receptors in the high-affinity state decreases after binding with an agonist that recruits arrestin.

DA release is measured with PET or SPECT by assessing the difference in binding potential for radiotracers



that label DA  $D_{2/3}$ Rs after a dopaminergic challenge as compared to a baseline condition [8,21,25]. DA can displace the radiotracer from the receptor (competition model), but the lower binding potential after a DA challenge may also be explained partly by internalization of DA  $D_{2/3}$ Rs. In a typical PET/SPECT study, DA release is measured 1 h after a DA challenge [8,21], and internalization of DA  $D_{2/3}$ Rs has been reported in a  $^{11}\text{C}$ -raclopride PET study in cats already 1 h after the administration of the DA releaser amphetamine [26]. Moreover, Guo and co-workers [27] demonstrated a lower binding affinity of agonist and antagonist radiotracers for internalized DA  $D_{2/3}$ Rs, possibly reflecting a poorer accessibility than to surface receptors. Since, the  $\beta$ -arrestin pathway plays an important role in the internalization of DA  $D_{2/3}$ Rs, it is important to know if a radiotracer is biased towards or away from  $\beta$ -arrestin translocation. Radiotracers that are biased towards cAMP may not promote  $\beta$ -arrestin-mediated receptor internalization and in theory may be more accurate tools to detect DA release. Recently cAMP-specific compounds have been developed for the dopamine  $D_2$ R and may offer the opportunity to be developed further to radioligands in future investigations [28]. These propositions may have implications for the interpretation of results from clinical studies with agonist tracers, particularly pharmacological challenge studies, e.g. with DA-releasing psychostimulants.

Since all tested agonists activate the cAMP as well as the  $\beta$ -arrestin-2 pathway, it is likely that they will also activate both GSK3 (via  $\beta$ -arrestin-2) and protein kinase A (via cAMP). This information is of importance when these radiopharmaceuticals are used to study or evaluate (novel) drugs. Dopaminergic drugs, like antipsychotics, but also drugs affecting other monoamine systems like the serotonin releaser fenfluramine, exert actions on the  $\beta$ -arrestin-2 pathway. Lithium, a drug used in the treatment of bipolar disorder, was found to have a direct inhibiting action on GSK3 [16]. Finally, compounds based on the aripiprazole scaffold were recently discovered that are functionally selective for the  $\beta$ -arrestin-2 pathway and that show robust antipsychotic effects in rodents [17,18]. So, it is likely that drugs that influence the canonical and/or the non-canonical pathway, may influence indirectly the *in vivo* binding of our presently tested  $D_{2/3}$ R agonists, including the radiotracers  $^{11}\text{C}$ -NPA and  $^{11}\text{C}$ -PHNO, which are frequently used in human studies [5,7].

Our novel finding that IBZM showed inverse agonism in the cAMP assay is in line with recent findings that the antipsychotics nemonapride and sulpiride (similar to IBZM, benzamides), and also antipsychotics from other chemical classes (e.g. butyrophenones like haloperidol), that were initially believed to be DA receptor neutral antagonists are now re-classified as inverse agonists by the

results of studies using functional assays [29]. It is alleged that inverse agonists bind preferentially to the inactive state of the receptor [30], so this might indicate that *in vivo*  $^{123}\text{I}$ -IBZM predominantly binds to striatal  $D_2$ Rs in their inactive low-affinity state. Since  $^{11}\text{C}$ -raclopride PET and  $^{18}\text{F}$ -fallypride are frequently used to assess DA release *in vivo* [5,7,23], it may be of relevance to test whether raclopride and fallypride are also inverse agonists for cAMP instead of antagonists. If our proposition is true that benzamide radiopharmaceuticals *in vivo* bind predominantly to DA  $D_{2/3}$ Rs in their low-affinity state, this will extend the discussion on why benzamides tracers are less sensitive than agonists  $D_{2/3}$ R radiopharmaceuticals (like  $^{11}\text{C}$ -PHNO) to detect DA release *in vivo* [5,7].

Nevertheless, more functional pharmacological characterization studies on agonist and antagonist (or inverse agonists)  $D_{2/3}$ R radiopharmaceuticals are needed to fully understand the mechanism how dopamine release can be detected *in vivo* using such radiotracers.

In this study, we focused on the  $D_2$ R. Since all developed radiopharmaceuticals to image this receptor also bind to the  $D_3$ R, it may be of interest to evaluate in future studies also how these radiotracers act on intracellular signalling of the  $D_3$ R.

## Conclusions

The agonist compounds tested exhibited agonism for both the cAMP and the  $\beta$ -arrestin-2 pathways, and no evidence was found for biased agonism. This information is crucial for the interpretation of findings with these tracers, especially in drug interaction studies. In addition, our data demonstrate, for the first time, that the benzamide IBZM is an antagonist for both  $\beta$ -arrestin-2 recruitment and cAMP formation, displaying inverse agonist properties for the latter.

## Competing interests

MCM is an employee of Boehringer Ingelheim, a company marketing the DA  $D_2$  agonist pramipexole. AGMJ is an employee of GE Healthcare, a company marketing the DA  $D_{2/3}$  radiopharmaceutical  $^{123}\text{I}$ -IBZM. JB is a consultant at GE Healthcare. The other authors declare that they have no competing interest.

## Authors' contributions

JPvW carried out the molecular signalling experiments, analysed the data, interpreted the results and drafted the manuscript. MCM was responsible for the design of the cAMP experiments, helped in analysing the data, interpreting the results and critically revising the manuscript. HMJ synthesized the aminomethylchroman molecules, helped in interpreting the results and in critically revising the manuscript. AGMJ helped interpreting the data and in critically revising the manuscript. PHE helped interpreting the data and in critically revising the manuscript. JB helped in the design of experiments, the interpretation of the data and in drafting the manuscript. All authors read and approved the final manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Acknowledgements

Work in the authors' lab has been supported by a grant from the Dutch Technology Foundation STW (grant 10127).

### Author details

<sup>1</sup>Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

<sup>2</sup>Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany. <sup>3</sup>SyMO-Chem BV, Eindhoven, The Netherlands. <sup>4</sup>GE Healthcare, Eindhoven, The Netherlands. <sup>5</sup>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Received: 14 August 2014 Accepted: 23 September 2014

Published online: 07 October 2014

### References

1. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E: **Distinct functions of the two isoforms of dopamine D2 receptors.** *Nature* 2000, **408**:199–203.
2. Jackson DM, Westlinddanielsson A: **Dopamine receptors: molecular-biology, biochemistry and behavioral-aspects.** *Pharmacol Ther* 1994, **64**:291–370.
3. Sibley DR, De Lean A, Creese I: **Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor.** *J Biol Chem* 1982, **257**:6351–6361.
4. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA: **Binding characteristics and sensitivity to endogenous dopamine of [<sup>11</sup>C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.** *J Neurochem* 2006, **97**:1089–1103.
5. Narendran R, Mason NS, Laymon CM, Lopresti BJ, Velasquez ND, May MA, Kendro S, Martinez D, Mathis CA, Frankle WG: **A comparative evaluation of the dopamine D2/3 agonist radiotracer [<sup>11</sup>C]-N-propyl-norapomorphine and antagonist [<sup>11</sup>C] raclopride to measure amphetamine-induced dopamine release in the human striatum.** *J Pharmacol Exp Ther* 2010, **333**:533–539.
6. Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper TB, Martinez D, Kegeles LS, Abi-Dargham A, Laruelle M: **In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[<sup>11</sup>C]propyl-norapomorphine ([<sup>11</sup>C]NPA) with the D2 receptor antagonist radiotracer [<sup>11</sup>C]-raclopride.** *Synapse* 2004, **52**:188–208.
7. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S, Plisson C, Miller SR, Huiban M, Beaver JD, Gunn RN, Laruelle M, Rabiner EA: **Within-subject comparison of [<sup>11</sup>C]-(+)-PHNO and [<sup>11</sup>C]raclopride sensitivity to acute amphetamine challenge in healthy humans.** *J Cerebr Blood Flow Metabol* 2012, **32**:127–136.
8. Laruelle M: **Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.** *J Cerebr Blood Flow Metabol* 2000, **20**:423–451.
9. Seneca N, Finnema SJ, Farde L, Gulyas B, Wikström HV, Halldin C, Innes RB: **Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [<sup>11</sup>C]MNPDA and antagonist [<sup>11</sup>C]raclopride.** *Synapse* 2006, **59**:260–269.
10. Skibjerg M, Namkung Y, Halldin C, Innes RB, Sibley DR: **Pharmacological characterization of 2-methoxy-N-propyl-norapomorphine's interactions with D2 and D3 dopamine receptors.** *Synapse* 2009, **63**:462–475.
11. Finnema S, Halldin C, Halldin C, Bang-Andersen B, Gulyas B, Bundgaard C, Wikström HV, Farde L: **Dopamine D2/3 receptor occupancy of apomorphine in the nonhuman primate brain- a comparative PET study with [<sup>11</sup>C] raclopride and [<sup>11</sup>C] MNPDA.** *Synapse* 2009, **63**:378–389.
12. McCormick PN, Kapur S, Seeman P, Wilson AA: **Dopamine D2 receptor radiotracers [<sup>11</sup>C]-(+)-PHNO and [<sup>3</sup>H] raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.** *Nucl Med Biol* 2008, **35**:11–17.
13. McCormick PN, Kapur S, Reckless G, Wilson AA: **Ex vivo [<sup>11</sup>C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.** *Synapse* 2009, **63**:998–1009.
14. Michel MC, Alewijnse AE: **Ligand-directed signaling: 50 ways to find a lover.** *Mol Pharmacol* 2007, **72**:1097–1099.
15. Beaulieu JM, Gainetdinov RR: **The physiology, signaling, and pharmacology of dopamine receptors.** *Pharmacol Rev* 2011, **63**:182–217.
16. Beaulieu JM, Gainetdinov RR, Caron MG: **The Akt-GSK-3 signaling cascade in the actions of dopamine.** *Trends Pharmacol Sci* 2007, **28**:166–172.
17. Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, Jin J: **Structure-functional selectivity relationship studies of  $\beta$ -arrestin-biased dopamine D2 receptor agonists.** *J Med Chem* 2012, **55**:7141–7153.
18. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Ydav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, Caron MG, Javitch JA, Roth BL, Jin J: **Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.** *Proc Natl Acad Sci U S A* 2011, **108**:18488–18493.
19. van Wieringen JP, Shalgunov V, Janssen HM, Franssen PM, Janssen AGM, Michel MC, Booij J, Elsinga PH: **Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging of dopamine D2/3 receptors in their high-affinity state.** *J Med Chem* 2014, **57**:291–410.
20. Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W: **<sup>123</sup>I- $\beta$ -CIT and <sup>123</sup>I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.** *Mov Disord* 1998, **13**:438–445.
21. Booij J, Korn P, Linszen DH, van Royen EA: **Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography.** *Eur J Nucl Med* 1997, **24**:674.
22. Depaulis T, Kumar Y, Johansson L, Ramsby S, Florvall L, Hall H, Angebymoller K, Ogren SO: **Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides.** *J Med Chem* 1985, **28**:1263–1269.
23. Skibjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innes RB: **D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.** *Neuroimage* 2010, **50**:1402–1407.
24. Seeman P: **Are dopamine D2 receptors out of control in psychosis?** *Progr Neuro-Psychopharmacol Biol Psych* 2013, **46**:146–152.
25. van de Giessen E, Celik F, Schweitzer DH, van den Brink W, Booij J: **Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity.** *J Psychopharmacol* 2014, **28**:866–873.
26. Ginovart N, Wilson AA, Houle S, Kapur S: **Amphetamine pretreatment induces a change in both D2-receptor density and apparent affinity: a [<sup>11</sup>C]raclopride positron emission tomography study in cats.** *Biol Psychiatry* 2004, **55**:1188–1194.
27. Guo N, Guo W, Kralikova M, Jiang M, Schieren I, Narendran R, Slifstein M, Abi-Dargham A, Laruelle M, Javitch JA, Rayport S: **Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers.** *Neuropsychopharmacol* 2009, **35**:806–817.
28. Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant -Genever M, Barnaeva E, Ferrer M, Javitch JA, Beuming T, Shi L, Southall NT, Marugan JJ, Sibley DR: **Discovery and characterization of a G protein-biased agonist that inhibits b-arrestin recruitment to the D2 dopamine receptor.** *Mol Pharmacol* 2014, **86**:96–105.
29. Hall DA, Strange PG: **Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors.** *Br J Pharmacol* 1997, **121**:731–736.
30. Rang HP, Dale MM, Ritter JM: **How drugs act: general principles.** In *Pharmacology*. 5th edition. Edited by Hunter L. London: Churchill Livingstone; 2003:17.

doi:10.1186/s13550-014-0053-3

Cite this article as: van Wieringen et al.: Agonist signalling properties of radiotracers used for imaging of dopamine D<sub>2/3</sub> receptors. *EJNMMI Research* 2014 **4**:53.